Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
| Revenue (Most Recent Fiscal Year) | $3.12B |
| Net Income (Most Recent Fiscal Year) | $1.14B |
| PE Ratio (Current Year Earnings Estimate) | 14.81 |
| PE Ratio (Trailing 12 Months) | 14.28 |
| PEG Ratio (Long Term Growth Estimate) | 7.09 |
| Price to Sales Ratio (Trailing 12 Months) | 4.64 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.95 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 16.10 |
| Pre-Tax Margin (Trailing 12 Months) | 42.63% |
| Net Margin (Trailing 12 Months) | 37.53% |
| Return on Equity (Trailing 12 Months) | 21.03% |
| Return on Assets (Trailing 12 Months) | 16.98% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.20 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 16.81 |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.26 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.54 |
| Earnings per Share (Most Recent Fiscal Year) | $1.46 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.99 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 641.54M |
| Free Float | 631.66M |
| Market Capitalization | $15.67B |
| Average Volume (Last 20 Days) | 1.17M |
| Beta (Past 60 Months) | 0.95 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.54% |
| Percentage Held By Institutions (Latest 13F Reports) | 7.07% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |